Dr. Leander Cannick III, MD

Dr. Cannick practices at AnMed North Campus - Mammography in Anderson, South Carolina.

Dr. Cannick's NPI, 1881705671, was assigned on August 31, 2006. Dr. Cannick graduated from University of South Carolina School of Medicine in 2012. Dr. Cannick holds South Carolina license 30455.

Dr. Cannick's primary practice is AnMed North Campus - Mammography, at 2000 E. Greenville Street, Anderson, SC 29621. The practice phone is (864) 512-6511.

Dr. Cannick's primary practice is AnMed North Campus - Mammography in Anderson, South Carolina. Dr. Cannick is also affiliated with AnMed Medical Center. The medical group on file is Blue Ridge Radiation Oncology. Dmand AI also links Dr. Cannick to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cannick practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Cannick's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Cannick's licenses on file in 2 states: South Carolina and North Carolina.

CMS data shows 2,819 Medicare services from Dr. Cannick across 19 procedure codes in 2024, for 240 Medicare patients. Medicare paid $189,113 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 240 Medicare patients who saw Dr. Cannick in 2024. The largest group is 65 to 74, with 100 patients. 75% of them have cancer, and 75% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cannick's median patient age at 70, with 54% women.

In 2024, Dr. Cannick wrote 182 Medicare Part D claims for 96 patients. 79% of them were for generic drugs. CMS names the drug for 91 of them, across 4 drugs with 11 or more claims each, at $2,054 in total drug cost. In 2023, CMS named 79 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Cannick for performance year 2024, reported individually. Dr. Cannick accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 2 papers to Dr. Cannick. Dr. Cannick's most frequent co-authors are Jennifer L. Harper, MD, David Taplin Marshall, MD and Ravi Shridhar, MD, PhD.

Dmand AI links Dr. Cannick to 10 clinical trials, 3 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Rectal Neoplasms, Rectal Diseases and Anal Canal Carcinoma. Alliance for Clinical Trials in Oncology sponsors the most, 2.

CMS Open Payments shows 269 general payments to Dr. Cannick from 70 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Novartis Pharmaceuticals Corporation paid the most, $493.

Dr. Cannick graduated from University of South Carolina School of Medicine in 2012.